While CIML natural killer immunotherapy can result in infection-like reactions, required prior chemo may cause infections, ...

Panelists discuss updated MonumenTAL-1 trial data demonstrating high response rates and prolonged survival with ...

Panelists discuss updated safety findings from GPRC5D-targeted bispecific therapy in relapsed/refractory multiple myeloma, ...

Patients receiving subcutaneous daratumumab have less chair time and premedication than those receiving IV formulation, says ...

Panelists discuss how patients newly diagnosed with multiple myeloma often face emotional and informational overload, but ...

Panelists discuss how patient portal use improves communication by allowing patients to report adverse effects with photos ...

A quality-adjusted time without symptoms or toxicity analysis identified better outcomes for patients with RCC treated with belzutifan vs everolimus.

A personalized neoantigen vaccine may be effective in patients with clear cell renal cell carcinoma, shared David A. Braun, ...

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of ...

Levels of kidney injuring molecule–1 appear to be predictive of therapeutic benefit in patients with renal cell carcinoma.

Based on durable response data, TAR-200 has been given priority review for the treatment of patients with high-risk ...

Panelists discuss how the COCOON study’s advanced dermatologic prophylaxis protocol, including systemic antibiotics and ...